Next Article in Journal
A One- or Two-Stage Revision of Fungal Prosthetic Joint Infection: A Review of Current Knowledge, Pitfalls and Recommendations
Previous Article in Journal
Antimicrobial Activity of Lavender Essential Oil from Lavandula angustifolia Mill.: In Vitro and In Silico Evaluation
Previous Article in Special Issue
7-O-Carboxylic Acid-Substituted 3-O-Alkyl Difluoroquercetin; An Aztreonam-Potentiating Agent Against Carbapenemase-Producing Pseudomonas aeruginosa Through Simultaneous Inhibition of Metallo-β-Lactamase and Efflux Pump
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 14
Issue 7
10.3390/antibiotics14070657
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Historical Overview of the Evolution of Multidrug-Resistant Gram-Negative Infections in Tunisia from 1999 to 2019

by
Lamia Kanzari
1,2,3,*,
Sana Ferjani
1,2,3,
Basma Mnif
4,5,
Faouzia Mahjoubi
4,5,
Mariem Zribi
6,
Khaoula Meftah
7,
Asma Ferjani
1,2,3,
Emna Mhiri
8,
Yomna Ben Lamine
9,
Yosr Kadri
10,11,
Habiba Naija
12,
Manel Hamdoun
13,
Yosra Chebbi
14,
Sarra Dhraief
15,
Naglaa Mohamed
16,
Hela Zaghden
17,
Lamia Thabet
15,
Wafa Achour
14,
Olfa Bahri
13,
Farouk Barguellil
12,18,
Maha Mastouri
10,11,
Sophia Besbes
9,
Leila Slim
8,
Hanen Smaoui
7,
Adnene Hammami
4,5 and
Ilhem Boutiba-Ben Boubaker
1,2,3add Show full author list remove Hide full author list
1
National Reference Laboratory on Antimicrobial Resistance Surveillance, Tunis 1006, Tunisia
2
Microbiology laboratory, Charles Nicolle Hospital, Tunis 1006, Tunisia
3
Research Laboratory Antimicrobial Resistance LR99ES09, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis 1007, Tunisia
4
Laboratory of Microbiology of Sfax University Hospital Center, Sfax 3000, Tunisia
5
Research Laboratory LR03SP03 “Micro-Organisme et Pathologie Humaine”, Faculty of Medicine, University of Sfax 3000, Tunisia
6
Laboratory of Microbiology, La Rabta Hospital, Tunis 1007, Tunisia
7
Laboratory of Microbiology, Bechir Hamza Children’s Hospital, Tunis 1006, Tunisia
8
Laboratory of Microbiology, Abderrahmen Mami Hospital, Ariana 2080, Tunisia
9
Laboratory of Microbiology, Mohamed Kassab Orthopaedics Institute, La Manouba 2010, Tunisia
10
Laboratory of Microbiology, Fatouma Bourguiba Hospital, Monastir 5000, Tunisia
11
Laboratory of Transmissible Diseases and Biologically Active Substances LR99ES27, Faculty of Pharmacy, University of Monastir, Monastir 5000, Tunisia
12
Laboratory of Microbiology, Military Hospital, Tunis 1008, Tunisia
13
Laboratory of Clinical Biology, Aziza Othmana Hospital, Tunis 1008, Tunisia
14
Laboratory Department, Bone and Marrow Transplantation Center, Tunis 1006, Tunisia
15
Laboratory of Clinical Biology, Burn and Trauma Center, Ben Arous 2013, Tunisia
16
Pfizer Inc., New York, NY 10001-2192, USA
17
Pfizer Inc., Tunis 1053, Tunisia
18
Faculty of Pharmacy, University of Monastir, Monastir 5000, Tunisia
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Antibiotics 2025, 14(7), 657; https://doi.org/10.3390/antibiotics14070657
Submission received: 6 May 2025 / Revised: 17 June 2025 / Accepted: 27 June 2025 / Published: 29 June 2025
(This article belongs to the Special Issue Antibiotics Resistance in Gram-Negative Bacteria, 2nd Edition)
Browse Figures
Versions Notes

Abstract

Background/Objectives: As antimicrobial resistance patterns of Gram-negative bacteria change over time, this study aimed to analyze the antimicrobial susceptibility trends of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii isolates in Tunisia. Methods: From 1999 to 2019, non-duplicate isolates of Gram-negative bacteria were collected from 11 Tunisian hospitals as part of an antimicrobial resistance surveillance program. Antimicrobial susceptibility testing was performed using the disk diffusion method according to the European Committee on Antimicrobial Susceptibility Testing guidelines. Results: Out of 213,434 isolates collected during the study period, 58.8% were E. coli, 22% were K. pneumoniae, 14.4% were A. baumannii, and 4.8% were P. aeruginosa, with 67% of the isolates sourced from urine samples. E. coli showed a significant increase in resistance to third-generation cephalosporins (3GC), from 5.4% in 2004 to 16.5% in 2019, but K. pneumoniae displayed a rising trend of resistance to imipenem, from 1% in 2005 to 18.6% in 2019; meanwhile, amikacin remained effective against K. pneumoniae isolates. P. aeruginosa did not exhibit a significant change in resistance to imipenem. A. baumannii had a high resistance rate to imipenem that increased from 34.5% in 2008 to 84.2% in 2019 and had low susceptibility rates to all other antibiotics tested. Conclusions: This study reveals high carbapenem resistance among K. pneumoniae and A. baumannii in Tunisia. A. baumannii shows alarming multidrug resistance that requires urgent control measures.

1. Introduction

Antimicrobial resistance (AMR) is a serious global public health concern and one of the biggest challenges humans face today. Multidrug-resistant (MDR) bacteria are spreading across the globe at a rate far faster than new antibiotics are being developed [1]. The World Health Organization (WHO) published a list of antimicrobial-resistant pathogens and classified them based on a priority for which new agents are urgently required. Gram-negative bacteria (GNBs) are of significant interest, as three GNBs (namely carbapenem-resistant Enterobacterales, carbapenem-resistant A. baumannii, and carbapenem-resistant P. aeruginosa) are of the highest priority and classified as critical [2]. The 2021–2022 antibiotic resistance-threats report by the Centers for Disease Control and Prevention (CDC) included seven pathogens that require immediate attention, of which four are GNBs [3]. Enterobacterales producing extended-spectrum β-lactamases (ESBLs), enzymes that hydrolyze extended-spectrum cephalosporins, are now more prevalent. Carbapenems are the alternative treatment option for ESBL-producing Enterobacterales. However, over the past few years, carbapenem resistance is on the rise, and new classes of antimicrobial agents are needed [4]. Misuse of antibiotics, in addition to the situation of MDR, has limited the therapeutic options for many infections to an alarming level [5].
MDR-GNB has been implicated in healthcare-associated infections, as well as community-acquired infections [1]. The most common infections caused by GNBs are bloodstream infections (BSIs), urinary tract infections (UTIs), respiratory tract infections (RTIs), surgical-site infections, and intra-abdominal infections (IAI) [6]. E. coli, K. pneumoniae (Enterobacterales), A. baumannii, and P. aeruginosa (non-fermenting GNBs) are frequently involved in these infections [7].
GNBs pose significant clinical challenges, primarily due to their inherent resistance to numerous antimicrobials, a consequence of their complex cell wall structure, and their exceptional capacity to acquire and disseminate additional resistance mechanisms [8]. This results in a substantial prevalence of MDR, extensively drug-resistant, and occasionally pandrug-resistant infections, which severely restrict therapeutic options and contribute to increased patient morbidity, mortality, and healthcare costs [9]. Clinically, these infections frequently present as severe and difficult-to-treat conditions, such as hospital-acquired pneumonia, bloodstream infections, complicated urinary tract infections, and intra-abdominal infections, particularly in immunocompromised or critically ill patients [10]. Current treatment strategies increasingly depend on last-resort antibiotics, including carbapenems, newer beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftazidime–avibactam, meropenem–vaborbactam, and imipenem–cilastatin–relebactam), cefiderocol, and older agents like colistin and fosfomycin, often employed in combination. This crisis prompts the development of novel therapeutics, including antibiotics, phage therapy, monoclonal antibodies, and innovative approaches to overcome resistance, offering potential solutions [11].
In the Middle East and North Africa region, Tunisia stands out for its high antibiotic consumption, with 38 defined doses administered per 1000 individuals daily. This consumption rate is only exceeded by Greece in the region and is about four times the global average [12]. In 2022, antibiotic use in a major Tunisian teaching hospital was nearly evenly divided between the “Access” (49.33%) and “Watch” (46.89%) groups, with a notable increase in the “Reserve” group (3.77%), indicating rising use of last-resort antibiotics [13]. The extensive use of antibiotics in Tunisia has contributed to the emergence and spread of antibiotic-resistant bacteria such as ESBL-producing Enterobacterales, a trend observed in increasing incidence rates in both hospital and community settings, and correlated with national antibiotic consumption data [13,14,15].
The prevalence of ESBL-producing Enterobacterales has risen sharply in Tunisia over the past three decades, affecting humans, animals, food, and the environment [16,17]. In urinary tract infections, 57% of third-generation cephalosporin-resistant Enterobacterales were ESBL producers, mainly E. coli and K. pneumoniae, with high resistance to commonly used antibiotics [16]. ESBL-producing Enterobacterales have been detected in various food and agricultural environments across Tunisia. Research indicates that these bacteria are present in vegetables (8.2%), soil (7.3%), and irrigation water sourced directly from farms (15.8%), as well as in vegetables available for sale in markets (8.9%), chicken (22.4% of feces and 63.8% of meat samples), and seafood (1.4% in fish and 1.6% in clams) [17,18,19]. The presence of MDR strains and mobile genetic elements in these bacteria raises concerns about the spread of antimicrobial resistance from food sources to the community [20,21].
Since 2006, several carbapenemase-producing GNBs, as well as carbapenem variants, have been detected in Tunisia [22]. Due to the lack of new agents to combat AMR, it is important to monitor the regional prevalence and antimicrobial resistance patterns, which can form the basis for effective empiric treatment. Surveillance programs help guide empiric therapy by providing useful data concerning organism distribution and resistance patterns [23].
In Tunisia, an antimicrobial resistance surveillance program called “L’AntibioRésistance en Tunisie” (LART) was designed in 1999 to track the evolution of antimicrobial resistance and detect the emergence of new resistance phenotypes [24]. In this study, we analyzed the distribution, prevalence, and susceptibility profiles of E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii isolates in Tunisia. The data on isolates were recovered from the LART surveillance period between 1999 and 2019. Antimicrobial susceptibility trends were also evaluated using samples collected from hospitalized and outpatients in Tunisia included in the LART database.

2. Results

2.1. Distribution of Gram-Negative Bacilli

Data on a total of 213,434 E. coli, K. pneumoniae, A. baumannii, and P. aeruginosa isolates were collected between 1999 and 2019, of which 58.8% were E. coli, 22% were K. pneumoniae, 14.4% were P. aeruginosa, and 4.8% were A. baumannii. The isolates were mainly collected from urines (67%), pus (11.5%), pulmonary samples (7.9%), blood cultures (6.6%), and punctures (1.8%) (Table 1).

2.2. Overall Frequency of Antibiotic Resistance

The overall frequency of resistance of E. coli and K. pneumoniae isolates to a wide range of antibiotics is summarized in Table 2. Overall, among the tested antimicrobial agents, E. coli and K. pneumoniae were most susceptible to imipenem (IMP) (carbapenems), followed by ertapenem (ETP), piperacillin–tazobactam (TZP), amikacin (AMK) (aminoglycoside), and cefoxitin (FOX) (cephalosporin). E. coli isolates showed higher susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and gentamicin (GEN) compared to K. pneumoniae isolates.
For non-fermenting GNBs, P. aeruginosa isolates had a more than 50% susceptibility rate against the tested antibiotics. They were most susceptible to CAZ and AMK, whereas A. baumannii isolates were resistant to most of the tested antimicrobial agents (Table 3).

2.3. Antibiotic Resistance Frequency by Samples and Type of Resistant Strains

Antibiotic resistance frequencies of E. coli and K. pneumoniae were analyzed in urine samples and blood cultures (Table 2). The susceptibility trend for E. coli and K. pneumoniae isolates in urine samples was similar to overall antibiotic susceptibility. E. coli, when isolated from blood cultures, showed a lower susceptibly for CTX and CAZ compared to overall susceptibility. Lower susceptibility rates were observed for all tested antibiotics, except for IMP, for K. pneumoniae isolates collected from blood cultures compared to isolates collected from urine samples and overall susceptibility.
Table 3 describes the antibiotic resistance frequencies of P. aeruginosa and A. baumannii in pulmonary samples and blood cultures. The antibiotic susceptibility profiles of P. aeruginosa and A. baumannii were similar for pulmonary samples and blood cultures.

2.4. Antimicrobial Susceptibility Trends

Figure 1 and Figure 2 and Supplementary Tables S1 and S2 depict the trends of resistance plus intermediate resistance of E. coli and K. pneumoniae to a selected number of antibiotics over the period 1999 to 2019. E. coli isolates were highly susceptible to IMP, AMK, and FOX throughout the study period (Table S1). However, susceptibility towards ciprofloxacin, cefotaxime, and gentamicin has been decreasing over the last few years (Figure 1). A statistically significant (p < 0.05) correlation was observed between E. coli and its resistance to CTX (r = 0.91, from 5.4% in 2004 to 16.5% in 2019), CIP (r = 0.93, from 7.9% in 1999 to 23.2% in 2019), and ERT (r = 0.89, from 0.2% in 2012 to 0.9% in 2019) during this period.
Over the last years, susceptibility of K. pneumoniae isolates to IMP, FOX, ciprofloxacin (CIP), and nalidixic acid (NA) has shown a decreasing trend (Table S2).
Figure 2 and Table S2 depict the trends of resistance plus intermediate resistance of K. pneumoniae to a selected number of antibiotics, namely CTX, IMP, ERT, CIP, GEN, and AMK, over the period from 1999 to 2019. Resistance of K. pneumoniae showed a very strong positive correlation (p < 0.005) to IMP (r = 0.92, from 1% in 2005 to 18.6% in 2019) and ERT (r = 0.78, from 5.6% in 2011 to 22.4% in 2019); and a strong positive correlation to FOX (r = 0.72, from 27.9% in 1999 to 48.2% in 2019) and CIP (r = 0.63, from 4% in 1999 to 37.9% in 2019). However, the resistance of K. pneumoniae to AMK showed a strong negative correlation, which was statistically significant (r = −0.74, p < 0.05).
Overall third-generation cephalosporin (3GC)-resistant E. coli strains had lower susceptibility towards all tested antibiotics, except FOX, ETP, IMP, and AMK. For 3GC-resistant K. pneumoniae, the resistance rate against FOX, ETP, and IMP has been increasing since 2013. However, the susceptibility of 3GC- and ERT-resistant K. pneumoniae strains against AMK has been variable throughout the study period. It varied from 26.2% in 2011 to 33.7% in 2019 for 3GC-resistant K. pneumoniae, and from 30.2% in 2012 to 61.5% in 2019 for ERT-resistant K. pneumoniae. Overall ERT-resistant strains had lower susceptibility towards all tested antibiotics (Table S5). Colistin (COL) and tigecycline (TIG) maintained their effectiveness against ERT-resistant K. pneumoniae and E. coli strains. However, their resistance rates for the period 2017–2019 seem to be increasing. TIG resistance rates varied from 2.7% to 20.9% for ERT-resistant K. pneumoniae strains and from 0% to 3.9% for ERT-resistant E. coli strains. For COL, it varied from 1.7% to 9.9% for ERT-resistant K. pneumoniae strains, and from 0% to 11.8% for ERT-resistant E. coli strains.
Figure 3 depicts the trends of resistance plus intermediate resistance of P. aeruginosa (1999–2019) and A. baumannii (2008–2019) to TZP, CAZ, IMP, GEN, AMK, and CIP. The increase in P. aeruginosa resistance to TZP from 18% in 2013 to 26% in 2019 was statistically significant (r = 0.81, p < 0.05); however, resistance to GEN decreased significantly from 48% in 1999 to 26.8% in 2019 (r= −0.6, p < 0.05). Correlation between P. aeruginosa and its resistance to CAZ (r = −02), IMP (r = 0.28), AMK (r = 0.86), and CIP (r = 0.42) over the period 1999–2019 was not found to be statistically significant (p > 0.05).
Concerning A. baumannii, a positive correlation was observed between A. baumannii and its resistance to IMP (r = 0.95), GEN (r = 0.74), and AMK (r = 0.86) over the period 2008–2019 and TZP (r = 0.89) over the period 2013–2019, which was statistically significant (p < 0.05).
In general, IMP-resistant P. aeruginosa and A. baumannii showed high resistance rates against all tested antibiotics; however, the resistance rate of A. baumannii was significantly higher compared to that of P. aeruginosa (Table S6). Those strains remain susceptible to COL (3.4% of IMP-resistant A. baumannii and 11.5% of IMP-resistant P. aeruginosa).

3. Discussion

In recent decades, the incidence of MDR organisms has been rising considerably in Tunisia, particularly in GNBs, which are frequently observed in clinical settings. As the antimicrobial susceptibility patterns of GNBs change over time, it is crucial to have real-time country-specific surveillance data to understand the impact of these infections and to guide preventive efforts [25]. This report evaluated the antimicrobial susceptibility trends of E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii isolates in Tunisia between 1999 and 2019, using data from LART surveillance program.
E. coli were the most commonly encountered GNBs (58.8%) which were predominantly implicated in UTIs, followed by BSIs. The findings are consistent with Guermazi-Toumi et al.’s [26] study conducted in Tunisia. During the study period, E. coli strains had high resistance rates for amoxicillin (AMX) (60%), amoxicillin–clavulanic acid (AMC) (25%), and trimethoprim sulfamethoxazole (SXT) (34%). The increasing resistance of E. coli to CIP has emerged as a significant concern, with reported rates reaching as high as 40% to 50% in Pakistan and Turkey, respectively [27,28]. In the present study, a statistically significant (p < 0.05) correlation was observed between E. coli and its resistance to CIP (r = 0.93). This rate is similar to Daoud et al.’s [25] study, which reported a resistance rate of 25.2% for fluoroquinolones (FQ) in Tunisia. The rise in CIP resistance is a result of overuse of CIP, especially among individuals exposed to FQ in the past six months [25]. Consistent with earlier findings, GEN and AMK (aminoglycosides) have preserved activity against E. coli and therefore can be used to treat infections [5,25,26,29]. The increase in resistance of E. coli to 3GC has been on the rise, as evidenced by a statistically significant positive correlation (r = 91). Between 2012 and 2019, the frequency of 3GC resistant strains ranged from 12% to 19%. In Tunisia, the prevalence of ESBL-producing E. coli has not been determined in a large-scale surveillance study. However, single-center retrospective studies reported an incidence ranging from 3.3% to 20% [26]. blaCTX-M-15 gene-mediated ESBLs are the most prevalent ESBL genotype encountered in Tunisian hospitals [30]. Therefore, carbapenems are considered an alternative empiric treatment when there is a high prevalence of 3GC resistance [29,31]. Since 2011, carbapenem resistance (CR) has been identified in clinical isolates of E. coli, although it remains uncommon in Tunisia [22]. Colistin remains the last resort for treating severe infections caused by CR organisms [22,29].
K. pneumoniae were the second most frequently isolated GNBs which are the leading cause of UTIs, BSIs, and RTIs, as is consistent with another Tunisian study [26]. Over the course of study period, increased resistance has been observed in K. pneumoniae isolates against IMP (r = 0.92), FOX (r = 0.72) and CIP (r = 0.63). K. pneumoniae isolates have retained susceptibility towards AMK, carbapenems (IMP and ETP) and colistin. The results correlate with the global trend of resistance observed in K. pneumoniae [5,29,32,33]. The increase in prevalence of MDR pathogens in healthcare settings resulted in a preference for carbapenems to manage these infections that consequently led to over consumption of carbapenems [34]. A significant increase in CR K. pneumoniae (CRKP) was observed over the span of ten years, and this increase was primarily attributed to the presence of OXA-48-like, NDM-type, and KPC-type carbapenemases [34]. To address the challenge posed by CRKP, colistin was regarded as the final treatment choice; however, increased dependence on colistin has led to the development of colistin-resistant K. pneumoniae strains [34]. Recently approved combination agents such as ceftazidime–avibactam, imipenem–relebactam, ceftolazone–tazobactam, and meropenem–vaborbactam display activities against CRKP and could serve as better alternatives [29,31]. Unfortunately, only ceftazidime–avibactam and ceftolazone–tazobactam are currently available in Tunisia, and susceptibility testing for these antibiotics is conducted by very few laboratories [35,36].
P. aeruginosa, a commonly encountered non-fermentative GNB, is known to cause various infections ranging from UTIs to severe pneumonia and BSIs, especially among patients with compromised immune system and cystic fibrosis [37]. Pus, pulmonary, urine, and blood samples accounted for 30.5%, 28%, 20.6%, and 6% of the total isolates, respectively, which corresponded closely with Abdallah et al.’s study carried out in Tunisia [38]. During the study period, the correlation analysis suggests that resistance of P. aeruginosa to IMP has not increased to a statistically significant level. Earlier studies carried out in Tunisia showed the dissemination of VIM-2 carbapenemase [22] and, recently, the emergence of GES-5 and GES-9 carbapenemases [39]. This observation may indicate a rise in MDR rates within the P. aeruginosa isolates, posing a significant public health concern that is difficult to treat [31]. Newer combination therapies, such as ceftazidime–avibactam, imipenem–relebactam, and ceftolazone–tazobactam, could serve as an effective strategy to treat these infections, as demonstrated by their high susceptibility in a study conducted by Sastre-Femenia et al. [40].
A. baumannii, another essential non-fermentative GNB, contributes to RTIs, UTIs, and BSIs, predominantly sourced from pulmonary, urine, and blood culture samples. Managing infections caused by A. baumannii becomes challenging, as this organism shows resistance against multiple classes of antibiotics [31]. The current study reported that the antimicrobial susceptibility rate for all tested antibiotics was below 20%, while the resistance rate to IMP was 85.5% in 2019, which aligns with the findings of another Tunisian study [41]. Similar to the findings in the Nadia et al. study, this report also detected a statistically significant positive correlation (r = 0.95) between A. baumannii and its resistance to IMP from 2008 to 2019 [37]. In Tunisia, carbapenem resistance among A. baumannii species is generally associated with production of OXA-23, OXA-58, the intrinsic OXA-51 carbapenemases [22], and, recently, VIM-2 carbapenemase [42]. Globally, A. baumannii demonstrates a higher level of MDR compared to P. aeruginosa and K. pneumoniae [29]. Since MDR A. baumannii retains susceptibility to colistin, it may serve an option for treating infections caused by this pathogen.
This study offers several notable strengths. Its longitudinal design over two decades provides critical insights into resistance evolution. The large multicenter dataset, comprising over 213,000 isolates from 11 Tunisian hospitals, ensures broad representation. Furthermore, standardized testing based on EUCAST guidelines, with regular internal quality controls, ensures consistency across sites. However, some limitations must be acknowledged. The retrospective design of the study restricts the ability to control for confounding factors and changes in clinical or laboratory practices over time. Patient-level data, such as comorbidities, outcomes, and prior antibiotic use, were not available. In addition, molecular typing of resistance genes was not performed, which would have strengthened our understanding of resistance mechanisms. The gradual expansion of surveillance sites over the study period may also have introduced bias. Finally, although amikacin and colistin remain effective against many MDR isolates, testing for newer antibiotics was limited.
Despite these limitations, this study provides critical baseline data to support national and regional antimicrobial stewardship efforts. Ongoing surveillance, expanded molecular diagnostics, and access to newer antimicrobials are essential to address the rising threat of Gram-negative antimicrobial resistance in Tunisia.

4. Conclusions

In conclusion, this study provides a comprehensive 20-year analysis of antimicrobial resistance patterns among major Gram-negative pathogens in Tunisia, using data from the LART surveillance program. The findings reveal a substantial increase in resistance among E. coli to third-generation cephalosporins, ciprofloxacin, and ertapenem, and among K. pneumoniae to imipenem, cefoxitin, and ciprofloxacin—highlighting the growing threat of extended-spectrum β-lactamase and carbapenemase producers. A. baumannii exhibited alarmingly high resistance to most antibiotics, including a dramatic rise in imipenem resistance, while P. aeruginosa resistance trends remained relatively stable. These results underscore the urgency of addressing multidrug resistance in clinical settings and provide critical national-level data to inform antibiotic stewardship, empirical treatment protocols, and future AMR containment strategies in Tunisia and similar contexts. From a public health perspective, the study supports the need for strengthened national AMR surveillance; regulatory action to curb antibiotic misuse; and investment in access to newer, effective antimicrobials to mitigate the escalating burden of resistant infections.

5. Materials and Methods

5.1. Study Sites and Inclusion

This retrospective overview was conducted between January 1999 and December 2019 across several different healthcare facilities in Tunisia that were part of the AMR surveillance network during that time.
During the 20-year study period, a total of 11 Tunisian hospitals participated. During the period 1999–2010, AMR surveillance was carried out in four different university hospitals, three from the Greater Tunis and one from Sfax (regrouping two hospitals). Since 2011, the AMR surveillance was extended to 11 university hospitals. The key healthcare facilities of two major cities in Tunisia, Tunis and Sfax, were part of the surveillance throughout the study period. Greater Tunis and Sfax are two prominent urban areas in Tunisia with distinct socioeconomic and health profiles. As the capital and largest urban agglomeration, Greater Tunis has a significant concentration of the nation’s healthcare resources, accounting for a third of the country’s public hospital beds, with 6679 beds in 2023 [43]. Sfax, Tunisia’s second-largest city, is renowned for its industrial and commercial activities. It serves as a key medical hub for the country and attracts patients from neighboring regions. Sfax hosts prominent university hospitals, like Habib Bourguiba University Hospital and Hedi Chaker University Hospital, with 1814 beds in 2023 [43].
GNB isolates of E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii were collected from different samples, including blood cultures, urine, and pulmonary samples, from hospitalized patients and outpatients. Samples were collected using routine methods, and species were identified using conventional methods based on morphological characteristics (colony morphology, Gram staining, and lactose fermentation); and biochemical tests, including oxidase test, API® (BioMérieux, Marcy-l’Etoile, France), or Vitek®2 Compact (BioMérieux, Marcy-l’Etoile, France). This process of identifying bacterial species takes approximately 24–48 h.
Isolates from the environment, colonization, and duplicate isolates from the same patient were not included in the analysis. The isolates were obtained from surgery, medicine, gynecology, neonatology, pediatrics, emergency, intensive care, onco-hematology, and outpatient departments.

5.2. Antimicrobial Susceptibility Testing

Following the identification of species, antimicrobial susceptibility testing (AST) was performed using disk diffusion method through disc diffusion on Mueller–Hinton agar, according to EUCAST guidelines [44] that were applicable at the time of sample collection. First, a standardized inoculum was prepared by suspending bacterial colonies from a fresh culture in saline to achieve a turbidity equivalent to 0.5 McFarland standard. This suspension was then evenly spread on Mueller–Hinton agar plates using a sterile swab. Antimicrobial disks were placed on the inoculated agar surface within 15 min of inoculation. The plates were incubated at 35 ± 1 °C for 16–20 h aerobically. Antimicrobial agents tested against E. coli and K. pneumoniae isolates were as follows: amoxicillin, amoxicillin–clavulanic acid, ticarcillin, piperacillin–tazobactam, cefoxitin, cefotaxime, ceftazidime, imipenem, ertapenem, gentamicin, amikacin, colistin, nalidixic acid, ciprofloxacin, and trimethoprim–sulfamethoxazole. Antimicrobial agents tested against P. aeruginosa and A. baumannii isolates were ticarcillin, ticarcillin + clavulanic acid, piperacillin, piperacillin-tazobactam, ceftazidime, cefepime, imipenem, meropenem, gentamicin, amikacin, ciprofloxacin, fosfomycin, and colistin. For some antibiotics (including tigecycline for Enterobacterales other than E. coli), the minimum inhibitory concentration (MIC) was determined using the E-test (BioMérieux®, Marcy-l’Etoile, France) or MICE® (Oxoid, UK). The broth microdilution method using the UMIC (Biocentric®, Bandol, France) was performed for colistin for extensively resistant strains.
After incubation, the diameters of the inhibition zones and the MIC were measured and interpreted according to EUCAST breakpoint tables, using the version at the time of isolate testing over the 21-year study period. Internal quality control (IQC) was carried out weekly by testing the recommended control strains (E. coli ATCC25922 and P. aeruginosa ATCC 27853).
All the laboratories participating in the surveillance program followed a comparable methodology regarding bacterial species identification, antibiotic susceptibility testing, and interpretation.

5.3. Statistical Analysis

Data were entered into Excel spread sheets, and continuous variables were analyzed using descriptive statistics. The evolution of K. pneumoniae, E. coli, A. baumannii, and P. aeruginosa resistance over time was represented by line graphs. Spearman rank correlation coefficients were calculated between the years and the resistance variable for each bacterium using R 4.2.1. The results were considered statistically significant if p-value was <0.05.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/antibiotics14070657/s1, Table S1: Frequency of antibiotic resistance of E. coli isolates, including for urines and blood cultures, in Tunisia from 1999 to 2019. Table S2: Frequency of antibiotic resistance of K. pneumoniae isolates, including for urines and blood cultures, in Tunisia from 1999 to 2019. Table S3: Frequency of antibiotic resistance of Pseudomonas aeruginosa isolates, including for pulmonary samples and blood cultures, in Tunisia from 1999 to 2019. Table S4: Frequency of antibiotic resistance of Acinetobacter baumannii isolates, including for pulmonary samples and blood cultures, in Tunisia from 1999 to 2019. Table S5: Frequency of associated antibiotic resistance of third-generation cephalosporin-resistant and ertapenem-resistant K. pneumoniae and E. coli isolates in Tunisia from 2011 to 2019. Table S6: Frequency of associated antibiotic resistance of imipenem-resistant P. aeruginosa and A. baumannii isolates in Tunisia from 2011 to 2019.

Author Contributions

Conceptualization, L.K., A.H., I.B.-B.B., H.Z. and N.M.; methodology, L.K., A.H., I.B.-B.B., H.Z. and N.M.; soft-ware, L.K., H.Z. and N.M.; validation, L.K., I.B.-B.B. and A.H.; formal analysis, H.Z. and N.M.; investigation, L.K. and I.B.-B.B.; resources H.Z. and I.B.-B.B.; data curation, L.K., S.F., B.M., F.M., M.Z., K.M., A.F., E.M., Y.B.L., Y.K., H.N., M.H., Y.C., S.D., L.T., W.A., O.B., F.B., M.M., S.B., L.S., H.S., A.H. and I.B.-B.B.; writing—original draft preparation, H.Z. and N.M.; writing—review and editing, L.K. and I.B.-B.B.; supervision, H.Z., N.M. and I.B.-B.B.; project administration, H.Z., N.M. and I.B.-B.B.; funding acquisition, H.Z. and N.M. All authors have read and agreed to the published version of the manuscript.

Funding

This work was financially supported by the Ministry of Health of Tunisia. Medical-writing and biostatistics assistance was funded by Pfizer rc0170146301.

Institutional Review Board Statement

Ethical approval for the study was obtained from the local ethics committee of Charles Nicolle Hospital on 1 November 2021.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available upon request from the corresponding author.

Acknowledgments

The authors acknowledge Dimpal Thakkar from Medical Excellence, Pfizer Ltd., for providing medical-writing assistance.

Conflicts of Interest

Naglaa Mohamed and Hela Mallek are employees of the company Pfizer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
AMRantimicrobial resistance
AMCamoxicillin–clavulanic acid
AMKamikacin
AMXamoxicillin
ASTantimicrobial susceptibility testing
BSIbloodstream infections
CAZceftazidime
CDCCenters for Disease Control and Prevention
CIPciprofloxacin
CTXcefotaxime
COLcolistin
EUCASTEuropean Committee on Antimicrobial Susceptibility Testing
ESBLsextended-spectrum β-lactamases
ETPertapenem
FEPcefepime
FOSfosfomycin
FOXcefoxitin
GENgentamicin
GNBsGram-negative bacteria
IAIintra-abdominal infections
IMPimipenem
IQCinternal quality control
LARTL’AntibioRésistance en Tunisie
MEMmeropenem
MDRmultidrug-resistant
NALnalidixic acid
PIPpiperacillin
RTIsrespiratory tract infections
SXTtrimethoprim–sulfamethoxazole
TIC ticarcillin
TIMticarcillin–clavulanic acid
TZPpiperacillin-tazobactam
UTIsurinary tract infections
3GCs3rd-generation cephalosporins

References

  1. Oli, A.N.; Itumo, C.J.; Okam, P.C.; Ezebialu, I.U.; Okeke, K.N.; Ifezulike, C.C.; Ezeobi, I.; Emechebe, G.O.; Okezie, U.M.; Adejumo, S.A.; et al. Carbapenem-Resistant Enterobacteriaceae Posing a Dilemma in Effective Healthcare Delivery. Antibiotics 2019, 8, 156. [Google Scholar] [CrossRef] [PubMed]
  2. Bassetti, M.; Garau, J. Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections. J. Antimicrob. Chemother. 2021, 76 (Suppl. S4), iv23–iv37. [Google Scholar] [CrossRef]
  3. Antimicrobial Resistance Threats in the United States, 2021–2022|Antimicrobial Resistance|CDC. Available online: https://www.cdc.gov/antimicrobial-resistance/data-research/threats/update-2022.html (accessed on 25 May 2025).
  4. Mackow, N.A. and van Duin, D. Reviewing novel treatment options for carbapenem-resistant Enterobacterales. Expert Rev. Anti-Infect. Ther. 2024, 22, 71–85. [Google Scholar] [CrossRef] [PubMed]
  5. Ponce-de-Leon, A.; Rodríguez-Noriega, E.; Morfín-Otero, R.; Cornejo-Juárez, D.P.; Tinoco, J.C.; Martínez-Gamboa, A.; Gaona-Tapia, C.J.; Guerrero-Almeida, M.L.; Martin-Onraët, A.; Cervantes, J.L.V.; et al. Antimicrobial susceptibility of gram-negative bacilli isolated from intra-abdominal and urinary-tract infections in Mexico from 2009 to 2015: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). PLoS ONE 2018, 13, e0198621. [Google Scholar] [CrossRef]
  6. Breijyeh, Z.; Jubeh, B.; Karaman, R. Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. Molecules 2020, 25, 1340. [Google Scholar] [CrossRef] [PubMed]
  7. Mancuso, G.; Midiri, A.; Gerace, E.; Biondo, C. Bacterial Antibiotic Resistance: The Most Critical Pathogens. Pathogens 2021, 10, 1310. [Google Scholar] [CrossRef]
  8. Gauba, A.; Rahman, K.M. Evaluation of Antibiotic Resistance Mechanisms in Gram-Negative Bacteria. Antibiotics 2023, 12, 1590. [Google Scholar] [CrossRef]
  9. Yassin, A.; Huralska, M.; Pogue, J.M.; Dixit, D.; Sawyer, R.G.; Kaye, K.S. State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms. Clin. Infect. Dis. 2023, 77, e46–e56. [Google Scholar] [CrossRef]
  10. Bassetti, M.; Peghin, M.; Vena, A.; Giacobbe, D.R. Treatment of Infections Due to MDR Gram-Negative Bacteria. Front. Med. 2019, 6, 74. [Google Scholar] [CrossRef]
  11. Larcher, R.; Laffont-Lozes, P.; Roger, C.; Doncesco, R.; Groul-Viaud, C.; Martin, A.; Loubet, P.; Lavigne, J.-P.; Pantel, A.; Sotto, A. Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study. Front. Cell. Infect. Microbiol. 2022, 12, 1048633. [Google Scholar] [CrossRef]
  12. Browne, A.J.; Chipeta, M.G.; Haines-Woodhouse, G.; Kumaran, E.P.A.; Hamadani, B.H.K.; Zaraa, S.; Henry, N.J.; Deshpande, A.; Reiner, R.C.; Day, N.P.J.; et al. Global antibiotic consumption and usage in humans, 2000–2018: A spatial modelling study. Lancet Planet. Health 2021, 5, e893–e904. [Google Scholar] [CrossRef] [PubMed]
  13. Kasbi, Y.; Sellami, F.; Ferjani, A.; Abbassi, A.; Ben Boubaker, I.B. Pharmaco-Epidemiological Study and Correlation Between Antibiotic Resistance and Antibiotic Consumption in a Tunisian Teaching Hospital from 2010 to 2022. Antibiotics 2025, 14, 135. [Google Scholar] [CrossRef]
  14. Sallem, N.; Ben Mansour, N.; Amri, H.; Boudaoura, M.; Gargouri, O.; Mahjoubi, F.; Hammami, A.; Mnif, B.; Chow, S.-K. Extended-spectrum beta-lactamase- and carbapenemase-producing Escherichia coli isolates causing hospital- and community-acquired infections in Tunisia (2001–2019): Expansion of CTX-M-15-C2 and CTX-M-27-C1 ST131 subclades. Microbiol. Spectr. 2024, 12, e0147124. [Google Scholar] [CrossRef]
  15. Mansour, W. Tunisian antibiotic resistance problems: Three contexts but one health. Afr. Health Sci. 2018, 18, 1202–1203. [Google Scholar] [CrossRef]
  16. Ben Hassena, A.; Guermazi-Toumi, S.; Amor, M.G.-B.; Saidani, M.; Tlili, S.; Khannous, L.; Gdoura, R.; Siala-Trigui, M. Detection of AmpC and ESBL-producing Enterobacterales isolated from urinary tract infections in Tunisia. Acta Microbiol. Et Immunol. Hung. 2022, 69, 46–55. [Google Scholar] [CrossRef]
  17. Sola, M.; Mani, Y.; Saras, E.; Drapeau, A.; Grami, R.; Aouni, M.; Madec, J.-Y.; Haenni, M.; Mansour, W. Prevalence and Characterization of Extended-Spectrum β-Lactamase- and Carbapenemase-Producing Enterobacterales from Tunisian Seafood. Microorganisms 2022, 10, 1364. [Google Scholar] [CrossRef] [PubMed]
  18. Ben Said, L.; Jouini, A.; Klibi, N.; Dziri, R.; Alonso, C.A.; Boudabous, A.; Ben Slama, K.; Torres, C. Detection of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in vegetables, soil and water of the farm environment in Tunisia. Int. J. Food Microbiol. 2015, 203, 86–92. [Google Scholar] [CrossRef] [PubMed]
  19. Hassen, B.; Abbassi, M.S.; Ruiz-Ripa, L.; Mama, O.M.; Hassen, A.; Torres, C.; Hammami, S. High prevalence of mcr-1 encoding colistin resistance and first identification of blaCTX-M-55 in ESBL/CMY-2-producing Escherichia coli isolated from chicken faeces and retail meat in Tunisia. Int. J. Food Microbiol. 2020, 318, 108478. [Google Scholar] [CrossRef]
  20. Moser, K.A.; Zhang, L.; Spicknall, I.; Braykov, N.P.; Levy, K.; Marrs, C.F.; Foxman, B.; Trueba, G.; Cevallos, W.; Goldstick, J.; et al. The Role of Mobile Genetic Elements in the Spread of Antimicrobial-Resistant Escherichia coli from Chickens to Humans in Small-Scale Production Poultry Operations in Rural Ecuador. Am. J. Epidemiol. 2018, 187, 558–567. [Google Scholar] [CrossRef]
  21. Partridge, S.R.; Kwong, S.M.; Firth, N.; Jensen, S.O. Mobile genetic elements associated with antimicrobial resistance. Clin. Microbiol. Rev. 2018, 31, e00088-17. [Google Scholar] [CrossRef]
  22. Dziri, O.; Dziri, R.; El Salabi, A.A.; Chouchani, C. Carbapenemase Producing Gram-Negative Bacteria in Tunisia: History of Thirteen Years of Challenge. Infect. Drug Resist. 2020, 13, 4177–4191. [Google Scholar] [CrossRef]
  23. Tamma, P.D.; Heil, E.L.; Justo, J.A.; Mathers, A.J.; Satlin, M.J.; Bonomo, R.A. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis. 2024, 78, ciae403. [Google Scholar] [CrossRef] [PubMed]
  24. Résistance Bactérienne. Available online: https://www.infectiologie.org.tn/resistance.php (accessed on 31 May 2025).
  25. Daoud, N.; Hamdoun, M.; Hannachi, H.; Gharsallah, C.; Mallekh, W.; Bahri, O. Antimicrobial Susceptibility Patterns of Escherichia coli among Tunisian Outpatients with Community-Acquired Urinary Tract Infection (2012–2018). Curr. Urol. 2020, 14, 200–205. [Google Scholar] [CrossRef]
  26. Guermazi-Toumi, S.; Boujlel, S.; Assoudi, M.; Issaoui, R.; Tlili, S.; Hlaiem, M.E. Susceptibility profiles of bacteria causing urinary tract infections in Southern Tunisia. J. Glob. Antimicrob. Resist. 2018, 12, 48–52. [Google Scholar] [CrossRef]
  27. Jadoon, R.J.; Jalal-Ud-Din, M.; Khan, S.A.E. Coli Resistance to Ciprofloxacin and Common Associated Factors. J. Coll Physicians Surg Pak. 2015, 25, 824–827. [Google Scholar] [PubMed]
  28. Yilmaz, N.; Agus, N.; Bayram, A.; Samlioglu, P.; Sirin, M.C.; Derici, Y.K.; Hanci, S.Y. Antimicrobial susceptibilities of Escherichia coli isolates as agents of community-acquired urinary tract infection (2008–2014). Urol. Res. Pr. 2016, 42, 32–36. [Google Scholar] [CrossRef]
  29. Veeraraghavan, B.; Jesudason, M.R.; Prakasah, J.A.J.; Anandan, S.; Sahni, R.D.; Pragasam, A.K.; Bakthavatchalam, Y.D.; Selvakumar, R.J.; Dhole, T.; Rodrigues, C.; et al. Antimicrobial susceptibility profiles of gram-negative bacteria causing infections collected across India during 2014–2016: Study for monitoring antimicrobial resistance trend report. Indian J. Med Microbiol. 2018, 36, 32–36. [Google Scholar] [CrossRef] [PubMed]
  30. Ayari, K.; Bourouis, A.; Chihi, H.; Mahrouki, S.; Naas, T.; Belhadj, O. Dissemination and genetic support of broad-spectrum beta-lactam-resistant Escherichia coli strain isolated from two Tunisian hospitals during 2004–2012. Afr. Health Sci. 2017, 17, 346–355. [Google Scholar] [CrossRef]
  31. Yan, M.; Zheng, B.; Li, Y.; Lv, Y. Antimicrobial Susceptibility Trends Among Gram-Negative Bacilli Causing Bloodstream Infections: Results from the China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2011–2020. Infect. Drug Resist. 2022, 15, 2325–2337. [Google Scholar] [CrossRef]
  32. Lin, W.-P.; Wang, J.-T.; Chang, S.-C.; Chang, F.-Y.; Fung, C.-P.; Chuang, Y.-C.; Chen, Y.-S.; Shiau, Y.-R.; Tan, M.-C.; Wang, H.-Y.; et al. The Antimicrobial Susceptibility of Klebsiella pneumoniae from Community Settings in Taiwan, a Trend Analysis. Sci. Rep. 2016, 6, 36280. [Google Scholar] [CrossRef]
  33. Bouchillon, S.K.; Badal, R.E.; Hoban, D.J.; Hawser, S.P. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: Results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009–2011. Clin. Ther. 2013, 35, 872–877. [Google Scholar] [CrossRef]
  34. Mansour, W.; Haenni, M.; Saras, E.; Grami, R.; Mani, Y.; Khalifa, A.B.H.; Atrouss, S.E.; Kheder, M.; Hassen, M.F.; Boujâafar, N.; et al. Outbreak of colistin-resistant carbapenemase-producing Klebsiella pneumoniae in Tunisia. J. Glob. Antimicrob. Resist. 2017, 10, 88–94. [Google Scholar] [CrossRef]
  35. Monography-Ceftazidime Avibactam-Stabilis 4.0. Available online: https://www.stabilis.org/Monographie.php?IdMolecule=997 (accessed on 17 June 2025).
  36. Megdiche, Z.; Lamloumi, M.; Maamar, B.; Dhraief, S.; Messadi, A.A.; Thabet, L. In vitro activity of ceftazidime- avibactam and ceftolozane- tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas æruginosa: Results from a trauma center and burn unit in Tunisia. Ann Burn. Fire Disasters 2025, 38, 31–37. [Google Scholar]
  37. Fethi, M.; Rojo-Bezares, B.; Arfaoui, A.; Dziri, R.; Chichón, G.; Barguellil, F.; López, M.; El Asli, M.S.; Toledano, P.; Ouzari, H.-I.; et al. High Prevalence of GES-5 Variant and Co-Expression of VIM-2 and GES-45 among Clinical Pseudomonas aeruginosa Strains in Tunisia. Antibiotics 2023, 12, 1394. [Google Scholar] [CrossRef]
  38. Abdallah, H.B.; Noomen, S.; Khélifa, A.B.E.; Sahnoun, O.; Elargoubi, A.; Mastouri, M. Susceptibility patterns of Pseudomonas aeruginosa strains isolated in the Monastir region, Tunisia. Med. Et Mal. Infect. 2008, 38, 554–556. [Google Scholar] [CrossRef] [PubMed]
  39. Ferjani, S.; Maamar, E.; Ferjani, A.; Kanzari, L.; Ben Boubaker, I.B. Evaluation of Three Carbapenemase-Phenotypic Detection Methods and Emergence of Diverse VIM and GES Variants among Pseudomonas aeruginosa Isolates in Tunisia. Antibiotics 2022, 11, 858. [Google Scholar] [CrossRef]
  40. Sastre-Femenia, M.À.; Fernández-Muñoz, A.; Gomis-Font, M.A.; Taltavull, B.; López-Causapé, C.; Arca-Suárez, J.; Martínez-Martínez, L.; Cantón, R.; Larrosa, N.; Oteo-Iglesias, J.; et al. Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: A nation-wide five-year time lapse analysis. Lancet Reg. Health-Eur. 2023, 34, 100736. [Google Scholar] [CrossRef] [PubMed]
  41. Nadia, J.; Wejdene, M.; Bonnin, R.A.; Meriam, G.; Cherifa, C.; Rachida, G.; Nesrine, K.; Noureddine, B.; Olfa, B.; Thierry, N. Temporal Variation in Antibiotic Resistance of Acinetobacter baumannii in a Teaching Hospital in Tunisia: Correlation with Antimicrobial Consumption. Open Microbiol. J. 2019, 13, 106–111. [Google Scholar] [CrossRef]
  42. Ferjani, S.; Kanzari, L.; Maamar, E.; Hamzaoui, Z.; Rehaiem, A.; Ferjani, A.; Boubaker, I.B.-B. Extensively drug-resistant Acinetobacter baumannii co-producing VIM-2 and OXA-23 in intensive care units: Results of a one-day point prevalence in a Tunisian hospital. Infect. Dis. Now 2022, 52, 426–431. [Google Scholar] [CrossRef]
  43. Tunisia in Figures 2022. Institut National de Statistiques/Publications|INS. Available online: https://www.ins.tn/publication (accessed on 29 May 2025).
  44. Eucast: Clinical Breakpoints and Dosing of Antibiotics. Available online: http://www.eucast.org/clinical_breakpoints (accessed on 1 January 2020).
Antibiotics 14 00657 g001
Figure 1. Trend of antibiotic resistance (R + I) of E. coli in Tunisia from 1999 to 2019. Resistant (R), Intermediate (I).
Figure 1. Trend of antibiotic resistance (R + I) of E. coli in Tunisia from 1999 to 2019. Resistant (R), Intermediate (I).
Antibiotics 14 00657 g001
Antibiotics 14 00657 g002
Figure 2. Trend of antibiotic resistance (R + I) of K. pneumoniae in Tunisia from 1999 to 2019. Resistant (R). Intermediate (I).
Figure 2. Trend of antibiotic resistance (R + I) of K. pneumoniae in Tunisia from 1999 to 2019. Resistant (R). Intermediate (I).
Antibiotics 14 00657 g002
Antibiotics 14 00657 g003
Figure 3. Trend of antibiotic resistance (R + I) of P. aeruginosa (from 1999–2019) and A. baumannii (from 2008 to 2019) in Tunisia.
Figure 3. Trend of antibiotic resistance (R + I) of P. aeruginosa (from 1999–2019) and A. baumannii (from 2008 to 2019) in Tunisia.
Antibiotics 14 00657 g003
Table 1. Overall distribution of isolates categorized by samples from 1999 to 2019 in Tunisia.
Table 1. Overall distribution of isolates categorized by samples from 1999 to 2019 in Tunisia.
PathogenTotal (n)UrinePulmonaryPuncturesBlood CulturesPusOther *
E. coli125,552107,088-1735401076805039
K. pneumoniae47,06227,6904040766645062021914
P. aeruginosa30,681632885651041191393613473
A. baumannii10,139163042042071745 1262 1091
Total213,434142,73616,809374914,11824,50511,517
* Other: Devices, biopsies, stool, otorhinolaryngology, and neonatal samples. (-) No data available in the surveillance system database.
Table 2. Frequency of antibiotic resistance of E. coli and K. pneumoniae in Tunisia from 1999 to 2019: overall, urine, and blood cultures isolates.
Table 2. Frequency of antibiotic resistance of E. coli and K. pneumoniae in Tunisia from 1999 to 2019: overall, urine, and blood cultures isolates.
PathogenK. pneumoniae
(n = 47,062)		E. coli
(n= 125,552)
ResistanceOverall
(1999–2019)		Urine
(2004–2019)
n = 27,690		Blood Culture
(2004–2019)
n = 6450		Overall
(1999–2019)		Urine
1999–2019
n = 107,088		Blood Culture
(2004–2019)
n = 4010
n(%R)n(%R)n(%R)n(%R)n(%R)n(%R)
AMC12,934(27%)5917(25%)2165(39%)23,813(19%)20,144(19%)547(21%)
PTZ1911(4%)--329(6%)1135(1%)917(1%)49(2%)
FOX6295(13%)3014(13%)1092(20%)2350(2%)1664(2%)159(6%)
CTX18,773(40%)8268(35%)3353(60%)13,598(11%)11,269(11%)613(24%)
CAZ18,330(39%)8044(34%)3230(58%)11,602(9%)9647(9%)522(20%)
IMP2353(5%)750(3%)610(11%)86(0%)35(0%)10(0%)
ERT7530(16%)1806(11%)936(25%)291(0%)200(0%)22(1%)
GEN16,808(36%)6921(29%)2935(53%)13,224(11%)10,843(10%)478(18%)
AMK4948(11%)1929(8%)933(17%)1766(1%)1413(1%)78(3%)
NAL14,564(31%)7590(32%)2009(36%)30,085(24%)25,119(23%)824(32%)
CIP14,577(31%)7753(33%)2049(37%)23,572(19%)19,915(19%)670(26%)
SXT20,142(43%)19,29541%18,82444%52,731(42%)51,47641%62,77650%
n, number of resistant isolates; %R, percentage of resistance; amoxicillin–clavulanic acid (AMC); piperacillin–tazobactam (PTZ); cefoxitin (FOX); cefotaxime (CTX); ceftazidime (CAZ); imipenem (IMP); ertapenem (ETP); gentamicin (GEN); amikacin (AMK); nalidixic acid (NAL); ciprofloxacin (CIP); and trimethoprim–sulfamethoxazole (SXT).
Table 3. Frequency of antibiotic resistance of P. aeruginosa and A. baumannii in Tunisia from 1999 to 2019: overall, respiratory, and blood cultures isolates.
Table 3. Frequency of antibiotic resistance of P. aeruginosa and A. baumannii in Tunisia from 1999 to 2019: overall, respiratory, and blood cultures isolates.
PathogenP. aeruginosa
(n = 30,681)		A. baumannii
(n= 10,139)
ResistanceOverall
(1999–2019)		Pulmonary Samples
(2004–2019)
n = 8056		Blood Culture
(2004–2019)
n = 1858		Overall
(1999–2019)		Pulmonary Samples
(2008–2019)
n = 4204		Blood Culture
(2008–2019)
n = 1745
n(%R)n(%R)n(%R)n(%R)n(%R)n(%R)
PTZ2666 (9%)1039 (14%)280 (18%)5413 (53%)2423 (58%)848 (49%)
CAZ4868 (16%)1319 (18%)318 (20%)8245 (81%)3652 (87%)1382 (79%)
FEP2079 (7%)1010 (14%)187 (12%)5443 (54%)2403 (57%)896 (51%)
IMP5798 (19%)1745 (23%)394 (25%)7117 (70%)3233 (77%)1176 (67%)
MEM698 (2%)269 (4%)48 (3%)------
GEN7615 (25%)1554 (21%)340 (22%)7576 (75%)3241 (77%)1217 (70%)
AMK4459 (15%)1013 (14%)263 (17%)7049 (70%)3171 (75%)1117 (64%)
CIP6916 (23%)1750 (23%)320 (20%)8320 (82%)3688 (88%)1374 (79%)
n, number of resistant isolates; %, percentage of resistance; piperacillin–tazobactam (PTZ); ceftazidime (CAZ); cefepime (FEP);; imipenem (IMP); meropenem (MEM); gentamicin (GEN); amikacin (AMK); ciprofloxacin (CIP).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kanzari, L.; Ferjani, S.; Mnif, B.; Mahjoubi, F.; Zribi, M.; Meftah, K.; Ferjani, A.; Mhiri, E.; Ben Lamine, Y.; Kadri, Y.; et al. Historical Overview of the Evolution of Multidrug-Resistant Gram-Negative Infections in Tunisia from 1999 to 2019. Antibiotics 2025, 14, 657. https://doi.org/10.3390/antibiotics14070657

AMA Style

Kanzari L, Ferjani S, Mnif B, Mahjoubi F, Zribi M, Meftah K, Ferjani A, Mhiri E, Ben Lamine Y, Kadri Y, et al. Historical Overview of the Evolution of Multidrug-Resistant Gram-Negative Infections in Tunisia from 1999 to 2019. Antibiotics. 2025; 14(7):657. https://doi.org/10.3390/antibiotics14070657

Chicago/Turabian Style

Kanzari, Lamia, Sana Ferjani, Basma Mnif, Faouzia Mahjoubi, Mariem Zribi, Khaoula Meftah, Asma Ferjani, Emna Mhiri, Yomna Ben Lamine, Yosr Kadri, and et al. 2025. "Historical Overview of the Evolution of Multidrug-Resistant Gram-Negative Infections in Tunisia from 1999 to 2019" Antibiotics 14, no. 7: 657. https://doi.org/10.3390/antibiotics14070657

APA Style

Kanzari, L., Ferjani, S., Mnif, B., Mahjoubi, F., Zribi, M., Meftah, K., Ferjani, A., Mhiri, E., Ben Lamine, Y., Kadri, Y., Naija, H., Hamdoun, M., Chebbi, Y., Dhraief, S., Mohamed, N., Zaghden, H., Thabet, L., Achour, W., Bahri, O., ... Boutiba-Ben Boubaker, I. (2025). Historical Overview of the Evolution of Multidrug-Resistant Gram-Negative Infections in Tunisia from 1999 to 2019. Antibiotics, 14(7), 657. https://doi.org/10.3390/antibiotics14070657

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop